在2025年的夏天,医药行业迎来一场震动全球的交易:默沙东以高达100亿美元的价格收购呼吸新贵Verona Pharma,将其明星产品——PDE3/4双靶点抑制剂恩司芬群 (Ohtuvayre)收入囊中。对于熟悉资本市场的人而言,这不仅是一次常规的“补管线”并购,而是对呼吸领域未来价值的重大下注。但少有人注意到,就在默沙东高调入局之际,一家中国药企——健康元,早已悄然完成了更加宽广、更加立体的战略...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.